References Sikiric, P., et al
TRANSCEND-T2D-1: Retatrutide Phase 3 Diabetes Results (March 2026) First Phase 3 retatrutide trial in type 2 diabetes 16.8% weight loss and -2.0% A1C at 12 mg over 40 weeks
With us, youre not just a new client, youre part of a group that values your recovery and health
In the colon, myrosinase produced by the microbiota can catalyze the generation of a wide range of metabolites from glucosinolates, depending on the pH and the presence of cofactors (4, 5)
Oral Options Available in Tucson PlexusDx offers both compounded semaglutide injection and oral semaglutide to Tucson patients, allowing choice based on lifestyle and absorption preferences
Months 3 and Beyond: The Acceleration Phase Side effects resolve for 85% or more of users by week 12 to 14